Patient characteristics: rheumatology disease variables compared across patients who received cardiovascular disease risk assessments in the NOCAR project and those who did not
| RA | AS | PsA | SpA | |||||||||
| In NOCAR n=2004 | Not in NOCAR n=2479 | P values | In NOCAR n=722 | Not in NOCAR n=941 | P values | In NOCAR n=700 | Not in NOCAR n=1228 | P values | In NOCAR n=219 | Not in NOCAR n=496 | P values | |
| Disease duration | 8.8 (4.6–15.9) | 7.4 (2.8–14.3) | <0.001 | 12.1 (5.9–22.7) | 12.3 (5.0–24.7) | 0.61 | 8.3 (3.8–15.6) | 6.3 (1.8–13.7) | <0.001 | 3.5 (1.6–7.2) | 2.3 (0.7–5.6) | 0.03 |
| RF positive | 790 (67.6) | 768 (66.2) | 0.46 | – | – | – | – | – | – | – | – | – |
| aCCP positive | 1035 (75.1) | 1099 (73.7) | 0.37 | – | – | – | – | – | – | – | – | – |
| CRP | 3.00 (1.58–5.00) | 4.00 (2.00–7.00) | 0.001 | 3.00 (1.00–5.00) | 3.00 (1.00–5.00) | 0.02 | 3.00 (2.00–5.00) | 4.00 (2.00–6.00) | 0.86 | 3.00 (1.06–5.50) | 3.00 (1.00–5.00) | 0.50 |
| ESR | 14.7±13.3 | 17.4±16.4 | <0.001 | 10.5±9.7 | 12.5±12.8 | 0.003 | 13.4±14.4 | 13.6±12.5 | 0.79 | 12.7±11.3 | 11.8±12.2 | 0.39 |
| Patient’s global | 29.8±24.5 | 33.3±25.5 | <0.001 | 33.2±25.2 | 35.9±25.9 | 0.05 | 33.7±26.1 | 38.5±25.7 | <0.001 | 36.4±24.7 | 37.8±25.7 | 0.51 |
| Investigator’s global | 12.1±13.7 | 14.1±15.2 | <0.001 | 13.6±13.4 | 13.4±14.5 | 0.73 | 13.9±13.9 | 13.7±14.3 | 0.81 | 15.7±13.3 | 14.1±15.1 | 0.24 |
| SJC28 | 0.86±2.11 | 1.35±2.62 | <0.001 | 0.06±0.32 | 0.14±0.64 | 0.01 | 0.46±1.30 | 0.76±1.93 | 0.001 | 0.22±0.73 | 0.35±1.24 | 0.20 |
| TJC28 | 1.52±3.21 | 2.29±4.01 | <0.001 | 0.48±1.68 | 0.89±3.24 | 0.01 | 1.93±3.70 | 2.26±4.10 | 0.10 | 1.11±2.15 | 1.09±2.55 | 0.93 |
| DAS28 | 2.54±1.24 | 2.87±1.33 | <0.001 | – | – | – | – | – | – | – | – | – |
| CDAI | 6.46±6.99 | 7.52±7.60 | <0.001 | – | – | – | – | – | – | – | – | – |
| BASDAI | – | – | – | 3.05±2.19 | 3.22±2.26 | 0.17 | 2.72±2.20 | 3.22±2.27 | <0.001 | 3.48±2.16 | 3.61±2.36 | 0.55 |
| bDMARD, current | 971 (48.5) | 767 (30.9) | <0.001 | 502 (69.6) | 418 (44.4) | <0.001 | 424 (60.6) | 354 (28.8) | <0.001 | 127 (58.0) | 181 (36.5) | <0.001 |
| bDMARD, ever | 1116 (55.7) | 955 (38.5) | <0.001 | 563 (78.1) | 516 (54.8) | <0.001 | 478 (68.3) | 453 (36.9) | <0.001 | 155 (70.8) | 231 (46.6) | <0.001 |
| No of bDMARDs tried | 2.00 (2.00–3.00) | 2.00 (2.00–3.00) | <0.001 | 2.00 (2.00–3.00) | 2.00 (2.00–3.00) | 0.80 | 2.00 (1.00–3.00) | 2.00 (1.00–3.00) | 0.24 | 2.00 (1.00–3.00) | 2.00 (1.25–3.00) | 0.76 |
| sDMARD, current | 1533 (76.6) | 1823 (73.5) | 0.02 | 88 (12.2) | 78 (8.3) | 0.01 | 451 (64.4) | 708 (57.7) | 0.003 | 62 (28.3) | 132 (26.6) | 0.64 |
| sDMARD, ever | 1960 (97.9) | 2284 (92.1) | <0.001 | 230 (31.9) | 200 (21.2) | <0.001 | 631 (90.1) | 967 (78.7) | <0.001 | 102 (46.6) | 203 (40.9) | 0.16 |
| MTX, current | 1309 (65.4) | 1591 (64.1) | 0.38 | 64 (8.9) | 55 (5.8) | 0.02 | 386 (55.1) | 589 (48.0) | 0.002 | 44 (20.1) | 98 (19.8) | 0.92 |
| MTX, ever | 1893 (94.6) | 2154 (86.8) | <0.001 | 126 (17.5) | 119 (12.6) | 0.01 | 595 (85.0) | 892 (72.6) | <0.001 | 77 (35.2) | 148 (29.8) | 0.16 |
| Prednisolone, current | 680 (34.0) | 1092 (44.0) | <0.001 | 191 (26.5) | 234 (24.8) | 0.44 | 241 (34.4) | 383 (31.2) | 0.14 | 58 (26.5) | 107 (21.6) | 0.15 |
| Prednisolone, ever | 1376 (68.7) | 1694 (68.3) | 0.75 | 221 (30.7) | 267 (28.3) | 0.31 | 335 (47.9) | 537 (43.7) | 0.08 | 89 (40.6) | 158 (31.9) | 0.02 |
Variables expressed as number (%) for dichotomous variables, mean±SD for normally distributed variables and median (IQR) for non-normally distributed variables.
AS, ankylosing spondylitis; BASDAI, Bath ankylosing spondylitis disease activity index; CDAI, clinical disease activity index; CRP, Creactive protein; DAS28, disease activity score with 28 joints using ESR; ESR, erythrocyte sedimentation rate; MTX, Mmethotrexate; NOCAR, NOrwegian Collaboration of Atherosclerosis in patients with Rheumatic diseases; PsA, psoriatic arthritis; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC, swollen joint count; SpA, spondyloarthropathy; TJC, tender joint count; aCCP, anti-cyclic citrullinated peptide; bDMARD, biologic disease-modifying antirheumatic drug; sDMARD, synthetic disease-modifying antirheumatic drug.